Dr Reddy’s launches antibiotic drug in US

Tags: News
Indian drug maker Dr Reddy’s has launched a generic and low priced version of the brand Avelox which is under marketing license with Merck. For the US market, the brand has total sales of $195 million at the end of one year in December 2013, estimates IMS Health.

The tablets which have Moxifloxacin Hydrochloride as active ingredient would come in 400 mg form. “Presenty, the competition for the drug is low, with only two other generic players, that is Teva and Aurobindo Pharma with approvals. We expect Dr Reddy’s to post sales of $20 million and net profit $5 million for this drug,” said Sarabjit Kour Nangra, senior vice-president (research, pharma) — Angel Broking.

The anti-infective (bacterial infections) drug contains moxifloxacin which is associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is aggravated in patients above 60 years of age and taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. While Bayer Healthcare manufactures the branded drug, Merck distributes it.

trushnaudgirkar

@mydigitalfc.com

EDITORIAL OF THE DAY

  • No ifs and buts, please, in India’s engagement with Iran

    Some foreign policy purveyors in this country have for long insisted that India does not leverage its civilisational connections as it should or is ca

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Taslima Nasreen

Hate in the time of bhaijaan

A few days ago I went to watch Bajrangi Bhaijaan, ...

Purnendu Ghosh

Death reveals the true colours of life

Death is instantaneous but it comes progressively. Some say, death ...

Gautam Gupta

Our fashion schools need to notch it up

"Creativity is the key to success and primary education is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture